Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Delivers more "Good On" time with less frequent dosing compared to Immediate Release CD/LD
Underscores Amneal's leadership in Parkinson's disease and commitment to one million people currently living with Parkinson's disease in the U.S.
CREXONT commercial launch planned in September 2024
Posted In: AMRX